BNP Parisbas Securities has recommended investors to buy three pharmaceuticals stocks showing rising trend. These stocks are JB Chemicals & Pharmaceuticals Ltd, Dr. Lal Pathlabs Ltd, and Aurobindo Pharma Ltd. 2 of these pharma stocks are currently trading near their 52-week low price. If investors buy these stocks now, they will get maximum return 31% return. Check details below:
1. Buy JB Chemicals & Pharmaceuticals Ltd
BNP Paribas Ltd has assigned buy call to JB Chemicals & Pharmaceuticals with a target price of Rs 2342 apiece. The current market price of the stock is Rs 1952 apiece with intraday surge of 0.32%.
If you buy JB Chemicals & Pharmaceuticals Ltd, you will get 20% return. The stock's 52-week high is Rs 2149 apiece and 52-week low is Rs 1339 apiece, respectively. It has a market capitalisation of Rs 15,100 crore.
The mid cap stock came into existence in 1976 and has given return of 13% in last 1-year, 324% in last 3-years, and 480% in last 5-years.
2. Buy Dr. Lal Pathlabs Ltd
The analyst has recommended investors to buy Dr. Lal Pathlabs Ltd with a target price of Rs 2820 apiece. If you buy Dr. Lal Pathlabs Ltd now, you will get 31% likely return soon.
The mid cap stock operating Diagnostics industry has a market capitalisation of Rs 18038 crore. The current market price of the stock is Rs 2164 apiece with 52-week high quoted at Rs 3768 apiece and 52-week low at Rs 1805 apiece, respectively.
The stock is also trading near its 52-week low price and currently just 16% away from 52-week low price.
The shares of Dr Lal Pathlabs have rallied 33% in last 3-years and 135% in last 5-years. It has declined 41% in last 1-year.
3. Buy Aurobindo Pharma Ltd
The brokerage firm has given buy call to Aurobindo Pharma Ltd with a target price of Rs 564 apiece. The current market price of the stock is Rs 431 apiece with an intraday fall 3.33%. If you buy Aurobindo Pharma Ltd now, you will get potential 31% return.
The stock's 52-week high is Rs 730 apiece and 52-week low is Rs 429 apiece. The current stock price is now just 0.46% away from 52-week low price. The stock has declined 39% in last 1-year and 16% in last 3-months.
The large cap pharmaceuticals company was incorporated in 1986. The company has a market capitalisation of Rs 25,274 crore.
Disclaimer
The stocks have been picked from the brokerage report of BNP Parisbas Securities. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
More From GoodReturns

ATM Rules Changing From April 1, 2026: HDFC Bank, PNB, Bandhan Bank & Others Revise Cash Withdrawal Rules

Crash in Gold Rate in India by Rs 71,400 in Single Day; Will Gold Price Today Fall Below Rs 1.50 Lakh? Outlook

Gold & Silver Rates Today Live: MCX Gold Crashes By Rs 5,645, Silver Falls By Rs 16,540; 24K, 22K, 18K Gold

1:5 Split Soon? Vedanta Ltd To Consider 3rd Interim Dividend On March 23, Share Jumps; Record Date & Buy Call

Sleeper Vande Bharat Express New Routes Identified for Long Distance Travel

Gold & Silver Rates Today Live Updates: Will 24 Carat, 22 Carat, 18 Carat See Bullish Week Ahead?

Mega Gold Price Crash Alert! 24K Sinks Rs 1.36 Lakh/100 Gm In Week; Silver Sees Losses | March 23-27 Outlook

Gold & Silver Rates Today Live: MCX Gold Ends Above Rs 1.40 Lakh, Silver Up 1%; 24K, 22K, 18K Gold On March 24

Gold Rate Crashes Over Rs 1 Lakh in Single Day, Slips to Lowest Since January; Will Gold Price Today Decline?

Gold Price Crash May Fuel Jewellery Demand: Why Kalyan Jewellers Share Price Could Shine Despite 5% Dip

Fatal Crash In Gold Rates In India By Rs 1,03,200/100 Gm; Biggest Single-Day Fall In 24K, 22K, 18K Gold Prices



Click it and Unblock the Notifications